

Primary Aldosteronism in Diabetic Subjects with Resistant Hypertension

Received for publication 8 January 2007 and accepted in revised form 30 March 2007.

Guillermo E. Umpierrez, M.D.
Paul Cantey, M.D., M.P.H.
Dawn Smiley, M.D.
Andres Palacio, M.D.
Diana Temponi, M.D.
Karen Luster, M.D.
Arlene Chapman, M.D.

Department of Medicine, Emory University School of Medicine, Atlanta, Georgia

Short title: Primary Aldosteronism in Type 2 Diabetes

Acknowledgments:

Dr Umpierrez is supported by research grants from the American Diabetes Association (7-03-CR-35), American Heart Association (0555306B), and National Institutes of Health: R03 DK073190-01 and General Clinical Research Center Grant M01 RR-00039.

Correspondence:

Guillermo E. Umpierrez, M.D.
Associate Professor of Medicine
Associate Director, General Clinical Research Center
Emory University School of Medicine
Director, Diabetes and Endocrinology Section
Grady Health System
49 Jesse Hill Jr Dr
Atlanta, GA 30303
E-mail: geumpie@emory.edu

ABSTRACT

Background: Despite the high prevalence of hypertension in patients with type 2 diabetes, the prevalence of primary aldosteronism in this population has not been determined.

Methods: One hundred subjects with type 2 diabetes and resistant hypertension, defined as a blood pressure > 140/90 mm Hg despite the use of ≥ 3 antihypertensive agents, were screened for primary aldosteronism. Screening was performed by measuring plasma aldosterone (PAC)/plasma renin activity (PRA) ratio. Subjects with a PAC/PRA ratio $>30 \text{ ng}\cdot\text{mL}^{-1}\cdot\text{h}^{-1}$ underwent confirmatory salt load testing. Diagnostic criteria included a 24-hour urine aldosterone $\geq 12 \text{ mcg}$ during the third day of oral salt load or a PAC $\geq 5 \text{ ng/dL}$ after the 4-hour intravenous saline load.

Results: Thirty four subjects had a PAC/PRA ratio $>30 \text{ ng}\cdot\text{mL}^{-1}\cdot\text{h}^{-1}$. Fourteen subjects (14%, 95% CI: 7.2-20.8) had a confirmed diagnosis of primary aldosteronism. Ninety three patients were African Americans. There were no differences in age, glycemic control, and number of antihypertensive drugs between subjects with and without primary aldosteronism. Subjects with primary aldosteronism had lower serum potassium (3.7 ± 0.4 vs. $4.0 \pm 0.4 \text{ mmol/L}$, $p = 0.012$), higher PAC (15.6 ± 8 vs. $9.1 \pm 6 \text{ ng/dL}$, $p = 0.0016$), and higher PAC/PRA (98 ± 74 vs. $21 \pm 30 \text{ ng}\cdot\text{mL}^{-1}\cdot\text{h}^{-1}$, $p < 0.001$) than patients without primary aldosteronism.

Conclusion: Primary aldosteronism is common in diabetic patients with resistant hypertension, with a prevalence of 14%. Our results indicate that diabetic subjects with poorly controlled hypertension on ≥ 3 antihypertensive drugs should be screened for primary aldosteronism.

INTRODUCTION

Diabetes and hypertension coexist in approximately 40 to 60% of patients with type 2 diabetes [1, 2]. Diabetic subjects have a 1.5 – 3 times increased prevalence of hypertension compared to non-diabetics [2, 3], with 50% of adults with diabetes having hypertension at the time of diagnosis [4]. The coexistence of these two conditions is associated with increased risk of retinopathy, nephropathy, and cardiovascular disease [1, 5]. Randomized prospective clinical trials have shown that rigorous blood pressure control in patients with diabetes reduces the risk of microvascular complications, cardiovascular events and death [6-8]. The risk reduction seen with hypertension control in patients with diabetes is substantially greater than that seen in persons in the general population who have similar blood pressure levels [9]. Epidemiological analyses show that in diabetic subjects a blood pressure > 120/70 mmHg is associated with increased cardiovascular event rates and mortality [3, 9]. There is no threshold value for blood pressure, and risk continues to decrease well into the normal range. Based on these findings, the Professional Practice Committee of the American Diabetes Association recommended a blood pressure goal of < 130/80 mmHg for adult patients with diabetes [2, 8]. Achieving blood pressure control in subjects with diabetes, however, is difficult and frequently requires the use of ≥ 3 antihypertensive agents [10, 11]. Less than 50% of people with diabetes achieve blood pressure goals [5].

Resistant hypertension, defined as a failure of concomitant use of ≥ 3 different classes of antihypertensive agents to control blood pressure to < 140/90 mm Hg, is a serious and common problem. It is present in 10 to 30% of patients with essential hypertension [12, 13]. Patients with resistant hypertension seem to differ from other

hypertensive subjects in three ways: they have more severe hypertension at diagnosis, they develop more end-organ damage, and they are more likely to have secondary hypertension [12, 13]. Primary aldosteronism is the most common cause of mineralocorticoid hypertension. Primary aldosteronism was previously believed to account for less than 1% of hypertensive patients; however, recent studies applying the PAC/PRA ratio as a screening test have reported a much higher prevalence of this disease, accounting for 10 to 32% of the patients with essential hypertension [11, 14-16] and 50% of patients with non-diuretic induced hypokalemia [17]. Despite the high prevalence of resistant hypertension among diabetic patients, the prevalence of primary aldosteronism is not known because screening for primary aldosteronism is seldom performed. Accordingly, this study aimed to determine the prevalence of primary aldosteronism in diabetic subjects with poorly controlled hypertension despite treatment with multiple antihypertensive agents.

MATERIAL AND METHODS

A total of 100 consecutive adult subjects with type 2 diabetes and resistant hypertension, defined as a blood pressure > 140/90 mm Hg despite the use of ≥ 3 antihypertensive agents, were screened for primary aldosteronism. Screening was performed while subjects continued their usual blood pressure medications, as it was felt to be unethical to stop blood pressure medications in this high-risk population. Subjects taking aldosterone antagonists were excluded from the study. Three blood pressure measurements were taken 5 minutes apart, and the average of the last two measurements were used for data analysis. Blood samples were drawn in the morning after the subject had been resting in a sitting position for 30 minutes. Screening studies

included measurement of PAC and PRA, and the calculation of the PAC/PRA ratio [18-20]. Hypertensive subjects with a PAC/PRA ratio $> 30 \text{ ng}\cdot\text{mL}^{-1}\cdot\text{h}^{-1}$ underwent further studies to confirm the diagnosis of primary aldosteronism. Subjects with a serum potassium $< 3.5 \text{ mEq/l}$ received KCl 40 mEq per day for 1 week. Once serum potassium was $\geq 3.5 \text{ mEq/l}$, subjects were re-screened (as hypokalemia suppresses PAC and lower the PAC/PRA ratio). Confirmatory studies included measurement of urinary aldosterone after a 3-day oral salt-load or the measurement of PAC after an intravenous saline load (Figure 1). The first 11 subjects in this study underwent the 3-day oral salt load. Most subjects were instructed to add 2g NaCl packages to each meal in addition to routine salt use for 3 consecutive days. During the third day of the oral salt load, a 24 hour urine collection was performed, and subjects brought the urine to the laboratory on the following morning before 9:00 a.m. To facilitate the conduct of the study by avoiding the 24 hour urine collection, we modified the protocol by substituting the oral salt load with a 4-hour intravenous saline suppression test. All remaining subjects underwent an IV saline suppression test. For this test, 2 liters of normal saline (0.9% solution) were infused over 4 hours at 500 ml/hour. The diagnosis of primary aldosteronism was established if the 24 hour urinary aldosterone concentration was $\geq 12 \text{ mcg}$ (33.3 nmol/d) during the third day of salt load, or if the PAC $\geq 5.0 \text{ ng/dL}$ after the 4-hour intravenous saline load [21-23]. Subjects with confirmed diagnosis of primary aldosteronism were referred to the endocrine service for adrenal imaging, localization studies and management. The research protocol was performed in the outpatient Grady Diabetes Clinic Research Laboratory or the Grady Clinical Research Center (GCRC).

All subjects in this study had a known history of type 2 diabetes for > 3 months, age

between 18 and 75 and were treated with ≥ 3 antihypertensive drugs. Exclusion criteria included treatment with spironolactone or eplerenone, hemoglobin A1C $> 9.0\%$, severe uncontrolled hypertension ($> 180/110 \text{ mm Hg}$), history of heart failure (New York Heart Association Class III or IV), angina pectoris, serum creatinine $> 1.8 \text{ mg/dl}$, pregnancy, breast-feeding, or on oral contraceptives, clinically relevant hepatic disease (ALT 2.5 times the upper limits of normal), drug or alcohol abuse, and subjects with known primary aldosteronism or suspected history of pheochromocytoma, Cushing's syndrome, or hyperthyroidism.

Analytic methods. Plasma aldosterone concentration, PRA, and urinary aldosterone were measured by commercial laboratories using standard techniques. PRA and PAC levels were measured by radioimmunoassay. The reference range for PRA is 1.31 to 3.95 ng/mL per hour. The reference range for PAC is 4.0 to 31.0 ng/dL. The reference range for urinary aldosterone is 2 to 16 g/24-hour. Plasma glucose was measured using the glucose oxidase method.

Statistical analysis. All data in the text, table and figures are expressed as mean \pm standard deviation unless otherwise noted. Comparisons of continuous variables between groups were carried out using unpaired t-test. The Wilcoxon test was used when data were skewed (i.e., PRA). For comparison of categorical variables, chi-square (χ^2) analyses were performed. A two-tailed p-value of < 0.05 was considered significant. All analysis was performed using SAS 9.1 statistical software (Cary, NC).

RESULTS

A total of 100 consecutive subjects with diabetes and resistant hypertension underwent screening. The clinical characteristics of study subjects are shown in Table 1. Most subjects in this study were from minority ethnic groups and included 93

blacks, 5 Caucasians, 1 Hispanic, and 1 Native American. Study subjects had a mean age of 59 ± 9 years (range 32 – 74 years), a mean duration of diabetes of 8.9 ± 7 years (range 3 months to 30 years), and a mean history of hypertension of 16.2 ± 12 years (range 1 – 48 years). The mean body mass index (BMI) was 34.4 ± 8 kg/m², with three-fourths of subjects having a BMI > 30 kg/m². The mean serum electrolytes were within normal limits. The mean serum potassium was 4.0 ± 0.4 mmol/l with only 15 subjects having a serum potassium ≤ 3.5 mmol/l. The mean systolic blood pressure was 157 ± 16 mm Hg and diastolic blood pressure was 90 ± 9 mm Hg. The mean number of antihypertensive drugs was 3.7 ± 0.8 . Ninety-eight percent of subjects were taking an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin receptor blocker (ARBs), 92% were taking a diuretic, 73% were taking a beta-blocker, 62% were taking a calcium channel blocker, and 31% were taking an alpha-blocker or other agent such as clonidine or hydralazine.

There were no statistically significant differences in ethnic distribution, age, years of hypertension, years of diabetes, BMI, blood pressure, hemoglobin A1c, number of antihypertensive agents or types of antihypertensive agent between subjects with and without primary aldosteronism. The mean systolic and diastolic blood pressures were 157 ± 15 mm Hg and 93 ± 10 mm Hg in subjects with primary aldosteronism and 158 ± 17 and 89 ± 8 mm Hg in subjects without primary aldosteronism. Similarly, we did not observe differences in the number of antihypertensive agents with 43% and 53% of subjects with and without primary aldosteronism receiving ≥ 4 drugs.

A total of 34 subjects (34%) had an increased PAC/PRA ratio >30 ng·mL⁻¹·h⁻¹, and 14 subjects (14%) had a confirmed diagnosis of primary aldosteronism. Compared to subjects with without primary

aldosteronism, subjects with primary aldosteronism had a lower serum potassium (3.7 ± 0.4 mmol/L vs. 4.0 ± 0.4 mmol/L, $p=0.012$), a lower serum creatinine (0.9 mg/dL ± 0.2 vs. 1.0 mg/dL ± 0.2 , $p=0.018$), a higher PAC (15.6 ± 8 ng/dL vs. 9.1 ng/dL ± 6 , $p=0.0016$), a lower PRA (0.2 ± 0.1 ng/mL vs. 5.5 ± 12 ng/mL, $p<0.001$), and a higher PAC/PRA ratio (98 ± 74 ng·mL⁻¹·h⁻¹ vs. 21 ± 30 ng·mL⁻¹·h⁻¹, $p<0.0001$).

Fifty-five subjects (55%) with resistant hypertension had suppressed PRA (< 1 ng/dL) or salt-sensitive hypertension. All subjects with primary aldosteronism and 41 subjects without primary aldosteronism had a PRA < 1 ng/dL. Twenty-two subjects without primary aldosteronism had a PAC/PRA ratio >30 ng·mL⁻¹·h⁻¹. A PAC ≥ 15 ng/dL, a commonly used criteria for screening of primary aldosteronism [20, 21, 23], was observed during the initial screening 18 subjects. Although the mean PAC during screening was 15.6 ± 8.3 ng/dL, 8 subjects with documented primary aldosteronism had a PAC < 15 ng/dL.

DISCUSSION

Approximately 20 million people in the US have diabetes mellitus [24], and another 50 million have hypertension [25]. Between 8 and 12 million diabetics have hypertension [1, 2, 25]. The co-existence of hypertension and diabetes accelerates the course of microvascular and macrovascular disease [1, 26, 27]. Hypertension markedly increases the risk for CVD and mortality in patients with type 2 diabetes. Randomized prospective clinical trials have shown that rigorous blood pressure control in patients with diabetes reduces macrovascular as well as microvascular complications [2, 6, 28, 29]. It was estimated that for each 10 mm Hg reduction in systolic blood pressure there is a 13% reduction in microvascular complications, a 12% decreased risk of fatal and non-fatal myocardial infarction, and a

17% decreased risk of death [6, 29]. In the HOT trial, a four-point difference in diastolic blood pressure (85 mm Hg vs. 81 mm Hg) resulted in a 51% decrease in risk for cardiovascular events in patients with diabetes [28]. Despite this strong evidence about the benefit of blood pressure control, nearly 75% of diabetic patients do not achieve good blood pressure control [25].

Primary aldosteronism is the most common endocrinologic cause of secondary hypertension. In recent years, with increased awareness and screening, the number of patients diagnosed with primary aldosteronism has increased by 5-to-10 fold accounting for 5-32% of the population with resistant hypertension [11, 14-16, 18, 19, 30-32]. Notably, however, there is little data that specifically examines the prevalence of primary aldosteronism in diabetic patients. Our study indicates that the prevalence of primary aldosteronism in patients with type 2 diabetes is similar to that reported in non-diabetic subjects with resistant hypertension [13, 20]. Of interest, we observed no differences in age, glucose control, or in the number or type of antihypertensive drugs between patients with and without primary aldosteronism. Given the importance of blood pressure control and the significant prevalence of primary aldosteronism in subjects with poorly controlled hypertension, all diabetics who have not met their blood pressure goals despite treatment with ≥ 3 drugs should be screened for primary aldosteronism.

The PAC/PRA ratio is considered the screening test of choice for primary aldosteronism [33, 34]. In the current study, patients were screened while being maintained on their prescribed antihypertensive medications. Angiotensin converting enzyme inhibitors, ARBs, and diuretics have been reported to increase PRA, calcium channel blockers to suppress aldosterone release, and beta blockers to

suppress PRA, thereby potentially confounding the assessment of PAC/PRA ratio [35-37]. Recent studies, however, have demonstrated that measurement of the PAC/PRA ratio to screen for primary aldosteronism is not significantly affected by concurrent antihypertensive [19, 20, 34, 38]. In addition, if there is a confounding effect, it would most likely result in an underestimation of the prevalence of PAC/PRA ratio, because the most commonly used antihypertensive agents in the current study (ACE-I, ARBs, and diuretics) tend to increase PRA, resulting in an increased number of falsely negative results [11, 13]. In our study population, the possible effects of continuing therapy during screening were unavoidable, as we felt that it would be unethical and unsafe to discontinue prescribed therapies in subjects who already had uncontrolled blood pressure control.

The PAC/PRA ratio has been criticized by some who claim that the ratio is overly renin-dependent and has low specificity [39]. The specificity of a high PAC/PRA ratio is only modest whether measured in participants on or off antihypertensive drug therapy (74% and 75%, respectively). To improve the specificity of the ratio (decrease the number of false positives), some have advocated the addition of a threshold value of aldosterone (> 15 ng/dL) as part of the screening criteria [20, 31]. Although such a strategy increases the specificity of the test, it has been shown to markedly decrease its sensitivity (increases the number of false negatives). Recently, Schwartz and Turner [19] reported that using a threshold value of PAC > 15 ng/dL, increased the specificity from 74% to 97% but markedly decreased the sensitivity from 73% to 33%. In agreement with this report, all subjects with primary aldosteronism in our study had a high PAC/PRA ratio (> 30 ng \cdot mL $^{-1}\cdot$ h $^{-1}$), however, only 43% of the subjects had a PAC > 15 ng/dL during the initial screening.

Given the importance of blood pressure control in the diabetic population, using screening criteria that would miss a substantial number of patients with an endocrinologic cause of hypertension does not make sense. Although eliminating a PAC threshold will increase false positive screens, these are easily distinguished from true positives with salt suppression testing. Thus, based on our findings and previous reports, the use of the PAC/PRA ratio may be preferable in screening for primary aldosteronism in patients with resistant hypertension.

We acknowledge several limitations in our study including a relative small number of subjects, the fact that most subjects (93%) were African-American, and the lack of a nondiabetic control group. The small number of subjects limits what can be said about the positive and negative predicative values of the PAC/PRA ratio. There is little data specific to African-American in regards to primary aldosteronism. Several reports have shown that extracellular fluid volume is an important contributor to the pathogenesis of low-renin hypertension and to hypertension in blacks [37-39]. Blacks have lower levels of plasma renin activity and more salt-sensitive (salt-dependent) hypertension than Caucasians [40, 42]. It has been estimated that the prevalence of salt-sensitive hypertension in hypertensive blacks is 50-73% versus 27-56% in hypertensive Caucasians [41, 43, 44]. Salt dependency is associated with favorable response to diuretics but poorer efficacy of ACE inhibitors or angiotensin receptor antagonists when these drugs are used as monotherapy [40, 41]. Moreover, salt dependency is not only a determinant of blood pressure response but is now classified as a

risk factor for cardiovascular and renal complications including left ventricular hypertrophy, microalbuminuria, insulin resistance and metabolic syndrome, and increased systemic and renal vascular resistance [12, 38, 40-42]. Despite the presence of lower renin activity in blacks, Calhoun et al [11] reported that in subjects with resistant hypertension, blacks have a similar prevalence of primary aldosteronism compared to Caucasians.

The American Diabetes Association advocates that hypertension should be treated aggressively to achieve and maintain a target blood pressure <130/80 mmHg [3]. In our study, we limited screening to subjects with a blood pressure > 140/90 mm Hg on ≥ 3 different antihypertensive agents. Thus, the prevalence of primary aldosteronism and the cost effectiveness of screening diabetic patients with blood pressure >130/80 mmHg needs to be examined in future studies.

In summary, we observed a prevalence of 14% of primary aldosteronism in diabetic subjects with poorly controlled hypertension on ≥ 3 antihypertensive agents. These results are of great clinical importance because patients with primary aldosteronism have a high incidence of renal and cardiovascular complications and increased mortality, and because aldosterone blockade can ameliorate renal and cardiovascular complications in patients with hypertension and with primary aldosteronism [34, 46-50]. Accordingly, diabetic patients with poorly controlled hypertension on ≥ 3 antihypertensive drugs should be screened for primary aldosteronism using the PAC/PRA ratio followed by salt suppression testing in those with a positive screening ratio.

REFERENCES

1. Sowers JR, Epstein M, Frohlich ED: Diabetes, Hypertension, and Cardiovascular Disease : An Update. *Hypertension* 2001; 37(4): 1053-1059.
2. Arauz-Pacheco C, Parrott MA, Raskin P: The Treatment of Hypertension in Adult Patients With Diabetes. *Diabetes Care* 2002; 25(1): 134-147.
3. Arauz-Pacheco C, Parrott MA, Raskin P: Hypertension management in adults with diabetes. *Diabetes Care* 2004; 27 Suppl 1: S65-7.
4. Klein R, Klein BEK, Lee KE, Cruickshanks KJ, Moss SE: The Incidence of Hypertension in Insulin-Dependent Diabetes. *Archives of Internal Medicine* 1996; 156(6): 622-27.
5. Bakris G, Sowers J, Epstein M, Williams M: Hypertension in patients with diabetes. Why is aggressive treatment essential? *Postgraduate Medicine* 2000; 107(2): 47-54.
6. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *Bmj* 1998; 317(7160): 703-13.
7. Tuomilehto J, Rastenyte D, Birkenhager WH, et al.: Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension. *N Engl J Med* 1999; 340(9): 677-684.
8. Standards of medical care in diabetes--2007. *Diabetes Care* 2007; 30 Suppl 1: S4-S41.
9. Vijan S, Hayward RA: Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. *Ann Intern Med* 2003; 138(7): 593-602.
10. Bloomgarden ZT: Diabetes and Hypertension. *Diabetes Care* 2001; 24(9): 1679-1684.
11. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P: Hyperaldosteronism among black and white subjects with resistant hypertension. *Hypertension* 2002; 40(6): 892-6.
12. McAlister FA, Lewanczuk RZ, Teo KK: Resistant hypertension: an overview. *Can J Cardiol* 1996; 12(9): 822-8.
13. Calhoun DA, Zaman MA, Nishizaka MK: Resistant hypertension. *Curr Hypertens Rep* 2002; 4(3): 221-8.
14. Fardella CE, Mosso L, Gomez-Sanchez C, et al.: Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology.[see comment]. *Journal of Clinical Endocrinology & Metabolism* 2000; 85(5): 1863-7.
15. Mulatero P, Stowasser M, Loh K-C, et al.: Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. *The Journal of Clinical Endocrinology and Metabolism* 2004; 89(3): 1045-1050.
16. Stewart PM: Mineralocorticoid hypertension. *Lancet* 1999; 353(9161): 1341-7.
17. Bravo EL: Primary aldosteronism. *Cardiology Clinics* 1988; 6(4): 509-15.
18. Blumenfeld JD, Sealey JE, Schlussek Y, et al.: Diagnosis and treatment of primary hyperaldosteronism.[see comment]. *Annals of Internal Medicine* 1994; 121(11): 877-85.
19. Schwartz GL, Turner ST: Screening for Primary Aldosteronism in Essential Hypertension: Diagnostic Accuracy of the Ratio of Plasma Aldosterone Concentration to Plasma Renin Activity. *Clin Chem* 2005; 51(2): 386-394.
20. Young WF, Jr.: Minireview: primary aldosteronism--changing concepts in diagnosis and treatment. *Endocrinology* 2003; 144(6): 2208-13.
21. Weinberger MH, Fineberg NS: The diagnosis of primary aldosteronism and separation of two major subtypes. *Archives of Internal Medicine* 1993; 153(18): 2125-9.
22. Kem DC, Weinberger MH, Mayes DM, Nugent CA: Saline suppression of plasma aldosterone in hypertension. *Archives of Internal Medicine* 1971; 128(3): 380-6.

23. Ganguly A: Primary aldosteronism. *New England Journal of Medicine* 1998; 339(25): 1828-34.
24. Cowie CC, Rust KF, Byrd-Holt DD, et al.: Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. *Diabetes Care* 2006; 29(6): 1263-8.
25. Hajjar I, Kotchen TA: Trends in Prevalence, Awareness, Treatment, and Control of Hypertension in the United States, 1988-2000. *JAMA* 2003; 290(2): 199-206.
26. Bakris GL: Maximizing Cardiorenal Benefit in the Management of Hypertension: Achieve Blood Pressure Goals. *J Clin Hypertens (Greenwich)* 1999; 1(2): 141-147.
27. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive Diabetes Therapy and Carotid Intima-Media Thickness in Type 1 Diabetes Mellitus. *N Engl J Med* 2003; 348(23): 2294-2303.
28. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *The Lancet* 1998; 351(9118): 1755-1762.
29. Adler AI, Stratton IM, Neil HAW, et al.: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. *BMJ* 2000; 321(7258): 412-419.
30. Gordon RD, Klemm SA, Stowasser M, Tunny TJ, Storie WJ, Rutherford JC: How common is primary aldosteronism? Is it the most frequent cause of curable hypertension? *Journal of Hypertension - Supplement* 1993; 11(5): S310-1.
31. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF, Jr.: Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. *Journal of Clinical Endocrinology & Metabolism* 2000; 85(8): 2854-9.
32. Stowasser M: Primary aldosteronism: revival of a syndrome.[comment]. *Journal of Hypertension* 2001; 19(3): 363-6.
33. Young WF, Jr.: Primary aldosteronism: management issues. *Annals of the New York Academy of Sciences* 2002; 970: 61-76.
34. Lim PO, Young WF, MacDonald TM: A review of the medical treatment of primary aldosteronism.[see comment]. *Journal of Hypertension* 2001; 19(3): 353-61.
35. Mulatero P, Rabbia F, Milan A, et al.: Drug Effects on Aldosterone/Plasma Renin Activity Ratio in Primary Aldosteronism. *Hypertension* 2002; 40(6): 897-902.
36. Gally BJ, Ahmad S, Xu L, Toivola B, Davidson RC: Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. *Am J Kidney Dis* 2001; 37(4): 699-705.
37. Schirpenbach C, Reincke M: Screening for primary aldosteronism. *Best Pract Res Clin Endocrinol Metab* 2006; 20(3): 369-84.
38. Hiramatsu K, Yamada T, Yukimura Y, et al.: A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. *Arch Intern Med* 1981; 141(12): 1589-93.
39. Montori VM, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST: Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. *Mayo Clinic Proceedings* 2001; 76: 877-882.
40. Sealey JE, Blumenfeld JD, Bell GM, Pecker MS, Sommers SC, Laragh JH: On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion and

- sodium excretion causing a hypertensive vasoconstriction-volume relationship. *J Hypertens* 1988; 6(10): 763-77.
41. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS: Definitions and characteristics of sodium sensitivity and blood pressure resistance. *Hypertension* 1986; 8(6 Pt 2): II127-34.
 42. Grim CE, Krishnaswami S, Gaudet D, et al.: 'Hyperaldosteronism' in stage 1 hypertension: ethnic differences. Abstracts from Scientific Sessions of the American Heart Association 2004: III-433.
 43. Weinberger MH: Salt sensitivity of blood pressure in humans. *Hypertension* 1996; 27(3 Pt 2): 481-90.
 44. Sullivan JM, Prewitt RL, Ratts TE: Sodium sensitivity in normotensive and borderline hypertensive humans. *Am J Med Sci* 1988; 295(4): 370-7.
 45. Corry DB, Tuck ML: The effect of aldosterone on glucose metabolism. *Current Hypertension Reports* 2003; 5(2): 106-9.
 46. Epstein M: Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. *American Journal of Kidney Diseases* 2001; 37(4): 677-88.
 47. Epstein M, Buckalew V, Altamirano J, Roniker B, Krause S, Kleiman J: Eplerenone reduces proteinuria in type II diabetes mellitus: implications for aldosterone involvement in the pathogenesis of renal dysfunction [abstract]. *Journal of the American College of Cardiology* 2002; 39(Suppl 1): 249A.
 48. Krum H, Nolly H, Workman D, et al.: Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients. *Hypertension* 2002; 40(2): 117-123.
 49. Mosso L, Carvajal C, Gonzalez A, et al.: Primary Aldosteronism and Hypertensive Disease. *Hypertension* 2003; 42(2): 161-165.
 50. Young WF, Jr.: Primary aldosteronism - treatment options. *Growth Horm IGF Res* 2003; 13 Suppl A: S102-8.

Table 1. Clinical Characteristics of Subjects with Resistant Hypertension with and Without Primary Aldosteronism

Variables	All Subjects	No Primary Aldosteronism	Primary Aldosteronism
Number of subjects	100	86	14
Age (yr)	59 ± 9	60 ± 9	57 ± 6
Race			
Black (%)	93 (93)	80 (93)	13 (93)
Caucasian/Hispanic/other	5/1/1	4/1/1	1/0/0
BMI (kg/m ²)	34.4 ± 8	34.5 ± 8	34.2 ± 8
Duration DM (yr)	8.9 ± 7	8.7 ± 7	9.8 ± 8
Duration hypertension (yr)	16 ± 12	16 ± 12	15 ± 7
SBP (mm Hg)	157 ± 16	158 ± 17	157 ± 15
DBP (mm HG)	90 ± 9	89 ± 8	93 ± 10
Mean # BP drugs*	3.7 ± 1	3.7 ± 1	3.6 ± 1
Number of subjects on BP agent (%)			
ACE-I or ARB	96 (98)	83 (99)	13 (93)
Diuretic	90 (92)	77 (92)	13 (93)
Beta Blocker	72 (74)	61 (73)	11 (79)
Calcium Channel Blocker	61 (62)	52 (62)	9 (64)
Other	30 (31)	26 (31)	4 (29)
Potassium (mEq/L)	4 ± 0.4	4 ± 0.4 [†]	3.7 ± 0.4 [†]
Creatinine (mg/dL)	1.0 ± 0.2	1.0 ± 0.2 [†]	0.9 ± 0.2 [†]
Hemoglobin A1C (%)	7.1 ± 1.4	7.1 ± 1.4	6.9 ± 1.1
PAC (ng/dL)	10 ± 7	9.1 ± 6*	15.6 ± 8*
PRA (ng/mL)	4.8 ± 11	5.5 ± 12	0.2 ± 0.1*
PAC/PRA ratio (ng/mL/hr)	33 ± 47	21 ± 30*	98 ± 74*

Except where noted values are mean ± standard deviation.

[†] p<0.05

* p<0.001

SBP: systolic blood pressure, DBP: diastolic blood pressure, ACE-I: angiotensin converting enzyme inhibitors, ARB: angiotensin receptor blockers, PAC: plasma aldosterone concentration, PRA: plasma renin activity. Plasma aldosterone is expressed in conventional units (ng/dL). To convert to SI Units (ng/dl to nmol/L = multiply by 0.0277).

Figure 1. Proposed Diagnostic Algorithm for Primary Aldosteronism

Graph 1. Proposed Diagnostic Algorithm for Primary Aldosteronism

